Nowadays, although people live in better conditions, they are generally in a sub-healthy physical state, often accompanied by chronic diseases, among which high blood lipids and high cholesterol are the most common. This may be related to people’s poor dietary habits and deteriorating environmental factors. Statins are mainly lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, resulvastatin and pitavastatin. Statin lipid-lowering drugs play a great role in the treatment and prevention of cardiovascular disease because of their ability to lower blood lipids, stabilize and improve atherosclerotic plaques, and improve blood vessel narrowing, etc. However, it is still important to note that “medicine can be toxic”. These drugs are especially likely to cause damage to liver function, so in the process of taking medication, it is necessary to consider how to prevent damage to the liver from statin lipid-lowering drugs, in the process of medication, it is necessary to pay attention to the following points: First, statin therapy before the start of liver enzyme testing, to see if there are no contraindications. The liver function should be rechecked 4-8 weeks after the start of treatment. If the standard is not reached in 3-6 months, the dose or type of statin should be adjusted and rechecked every 6-12 months after the standard is reached. Second, if the transaminases are elevated within 3 times of the upper limit of the normal value, they can be observed on the basis of the original dose or dose reduction, and some patients’ transaminases can return to normal. For patients whose transaminases are elevated more than 3 times the upper limit of normal value and combined with elevated total bilirubin, the drug should be suspended, but the liver function should be rechecked weekly until it returns to normal. The combination of statins and anti-hepatitis viral drugs may increase adverse reactions, and statins that are not metabolized by CYP3A4, such as pravastatin, can be chosen. If liver function damage is caused by statins, patients can also switch to other lipid-regulating drugs such as cholesterol absorption inhibitors (ezetimibe, etc.), niacin (vitamin E niacin capsules, etc.), bile acid sequestrants (kaufenamide), fibrates (fenofibrate, etc.), and preprotein convertase chymotrypsin 9 (PCSK9) inhibitors after liver function recovery.